Effects of Pioglitazone and Glimepiride in Hypertensive Patients - Relationship With AGE, Inflammatory Cytokines and Cardiac Markers -
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 16
- 试验地点
- 1
- 主要终点
- advanced glycation end-product (AGE)
研究概览
简要总结
Insulin resistance is often complicated with hypertension. AGE and inflammation play important roles in insulin resistance. Some studies reported that pioglitazone, insulin sensitizer, is effective for patients with insulin resistance, however, the mechanisms are still unclear. The aim of this study to evaluate the effect of pioglitazone compared with glimepiride on AGE, inflammatory cytokines and cardiac markers (BNP and echo) in hypertensive patients during oral glucose tolerance test.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 20 Years 至 —(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Hypertension with insulin resistance
排除标准
- •Chronic systolic heart failure, ACS
研究组 & 干预措施
glymepiride
干预措施: Pioglitazone (Drug)
结局指标
主要结局
advanced glycation end-product (AGE)
时间窗: 24 weeks
inflammatory cytokines (TNF-alfa, IL-6 and MCP-1)
时间窗: 24 weeks
cardiac function (echo and BNP)
时间窗: 24 weeks
次要结局
未报告次要终点
研究者
Kazuhide Ogino
Associate Professor
Tottori University Hospital
